These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11338177)

  • 21. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
    Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
    Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
    Ishida Y; Kuwahara I; Todaka K; Hashiguchi H; Nishimori T; Mitsuyama Y
    Brain Res; 1996 Jul; 727(1-2):205-11. PubMed ID: 8842399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
    Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
    Sader-Mazbar O; Loboda Y; Rabey MJ; Finberg JP
    Br J Pharmacol; 2013 Nov; 170(5):999-1013. PubMed ID: 23992249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats.
    Malone DT; Taylor DA
    Br J Pharmacol; 1999 Sep; 128(1):21-6. PubMed ID: 10498830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoflurane anesthesia inhibits clozapine- and risperidone-induced dopamine release and anesthesia-induced changes in dopamine metabolism was modified by fluoxetine in the rat striatum: an in vivo microdialysis study.
    Adachi YU; Yamada S; Satomoto M; Higuchi H; Watanabe K; Kazama T; Mimuro S; Sato S
    Neurochem Int; 2008 Feb; 52(3):384-91. PubMed ID: 17719143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
    Datla KP; Blunt SB; Dexter DT
    Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
    Xu K; Dluzen DE
    J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum.
    Maeda T; Kannari K; Suda T; Matsunaga M
    Brain Res; 1999 Jan; 817(1-2):185-91. PubMed ID: 9889362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
    Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
    Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
    Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
    Meissner W; Ravenscroft P; Reese R; Harnack D; Morgenstern R; Kupsch A; Klitgaard H; Bioulac B; Gross CE; Bezard E; Boraud T
    Neurobiol Dis; 2006 Jun; 22(3):586-98. PubMed ID: 16531050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease.
    Rocchitta G; Migheli R; Esposito G; Marchetti B; Desole MS; Miele E; Serra PA
    J Pineal Res; 2006 Apr; 40(3):204-13. PubMed ID: 16499555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
    Jackson D; Abercrombie ED; Zigmond MJ
    J Pharmacol Exp Ther; 1993 Nov; 267(2):912-8. PubMed ID: 8246167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Sahin G; Thompson LH; Lavisse S; Ozgur M; Rbah-Vidal L; Dollé F; Hantraye P; Kirik D
    PLoS One; 2014; 9(3):e90759. PubMed ID: 24614598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
    Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
    J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.